Anthropic filed for its hotly anticipate IPO on Monday — potentially the biggest initial offering in history — and the San Francisco area's luxury markets are banking on big business from freshly flush AI employees and early investors.

Sam Altman’s OpenAI is reportedly wrapping up a fundraising round that would value the company well above $1 trillion as it mulls when to go public.

Meta shares surged more than 4% in after-hours trading Wednesday after the Facebook parent reported a 26% jump in quarterly revenue.

Alphabet-owned Waymo is using Chinese-built vehicles to rapidly expand its nationwide robotaxi fleet – a controversial strategy that risks drawing the ire of US lawmakers who want to ban Chinese vehicles entirely.

Walmart’s multibillion-dollar push to replace human workers with robots is hitting snags as the machinery struggles to carry dog food and Thanksgiving turkeys or handle cardboard boxes, according to a report.

PepsiCo said it will raise prices on some snack and beverage products after its third-quarter results fell short of expectations, with beverage volumes down 2% and snack volumes flat. The move reverses a price-cut push launched in February to appeal to consumers strained by inflation.

AI company Anthropic is planning an initial public offering in mid-November that could value it at more than $2 trillion. In its prospectus, the company said it expects to commit $518 billion in coming years to cloud, computing and infrastructure obligations. It reported 2025 revenue of nearly $4.6 billion, up 12-fold from the prior year, alongside an operating loss of more than $8 billion and a net loss of $42 billion.

Eli Lilly’s triple-receptor agonist retatrutide (GLP-1/GIP/glucagon) delivered substantial weight loss in the Phase 3 Triumph-4 trial. Patients on the lowest 4 mg once-weekly dose lost an average of 29.8 pounds (12.7%), while those on the highest dose lost 49.6 pounds (20.8%). The company expects to submit the drug to the U.S. FDA for approval early next year, positioning it as the first therapy in its class to target all three metabolic receptors.

McDonald’s plans to introduce several new menu items, positioning them directly against rivals such as Starbucks and Chipotle. The company said roughly 30 million Americans are using GLP-1 drugs such as Ozempic. McDonald’s also said it will provide about $8.5 billion in support to franchisees through 2036 to modernize restaurants and advance its global growth strategy. Franchisees are expected to invest an additional roughly $800,000 to carry out the plan.